1,552
Views
15
CrossRef citations to date
0
Altmetric
Review

Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: A systematic review and meta-analysis

, , , , &
Pages 1418-1425 | Received 06 Oct 2014, Accepted 30 Dec 2014, Published online: 18 Jun 2015

References

  • Wang YL, Zhun QX, Lin GW, Yu YY, Chen ZL. Immunogenicity of live attenuated Japanese encephalitis vaccine in Xian Ju. Mod Pre Med 2008; 154
  • Kaltenbock A, Dubischar-Kastner K, Schuller E, Datla M, Klade CS, Kishore TSA. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 2010; 834–9; PMID:19857447; http://dx.doi.org/10.1016/j.vaccine.2009.10.024
  • Wang XX, Li YX, Yin ZD, Li JH, Ning GJ, Liang XF. Development on epidemiological charateristics and residual sequelae of Japanese encephalitis. Chinese J Vaccin Immun 2008:176–9
  • Zhang YP, Feng ZJ, CK.Lee. Japanese encephalitis prevention strategies in China. HenJ Prevent Med 2006:193–5
  • Jing C. Review of advances in Japanese encephalitis virus vaccines. J Path Biol 2010:375–7
  • Miyazaki C, Okada K, Ozaki T, Hirose M, Iribe K, Yokote H, Ishikawa Y, Togashi T, Ueda K. Phase III clinical trials comparing the immunogenicity and safety of the vero cell-derived Japanese encephalitis vaccine Encevac with those of mouse brain-derived vaccine by using the Beijing-1 strain. Clin Vaccine Immunol 2014; 21:188–95; PMID:24334689; http://dx.doi.org/10.1128/CVI.00377-13
  • Gowal D, Tahlan AK. Evaluation of effectiveness of mouse brain inactivated Japanese encephalitis vaccine produced in India. Indian J Med Res 1995; 102:267–71; PMID:8557319
  • Schioler KL, Samuel M, Wai KL. Vaccines for preventing Japanese encephalitis. Cochr Data Sys Rev 2007; PMID:17636750
  • Yin ZD, Luo HM, Li YX. Meta-analysis on serological effect of the primary vaccination for Japanese encephalitis of the literatures. Chinese J Vaccin Immun 2009; 15:501–6; PMID:20518324
  • Japanese encephalitis vaccine. Weekly Epidemiological Record 2006:331–340.
  • http://www.who.int/immunization/Japanese_encephalitis_Chinese.pdf
  • Bai ZY, Zhao GF, Liu J. The antibody response to the basic immunization of two forms of Japanese B encephalitis vaccine. Chinese J Vaccin Immun 2000:16–7
  • Chen HY, Zhang YF, Ma FB, Zhang JL, Diao LD, Zhang GF, Sun JS, Bai ZY. Observation of immune efficacy of the be attenuated Japanese encephalitis vaccine. Chinese J Vaccin Immun 1999:215–6
  • Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, Sabchareon A, Pancharoen C, Bouckenooghe A, Gailhardou S, Boaz M, Feroldi E. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr Infect Dis J 2010; 29:1111–7; PMID:20856164; http://dx.doi.org/10.1097/INF.0b013e3181f68e9c
  • Dai H, Chen HP, Hua RZ, Guo Xl, Zhang QD, Guo SH, Zhang YF, Dong CM, Wang MR, Diao LD, et al. Three-dose, inactivated Japanese encephalitis vaccine immunogenicity and safety trial. China Pub Health 1994:195–6; (in Chinese)
  • Dai H, Zhang YF, Diao LD, Feng BX, Xu AL, Guo JT. Immunogenicity of inactivated Japanese encephalitis vaccine (JEV-I(PHK)) in children China public health. 1997; 61 (in Chinese); PMID:9252251
  • Feroldi E, Pancharoen C, Kosalaraksa P, Chokephaibulkit K, Boaz M, Meric C, Hutagalung Y, Bouckenooghe A. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: A randomized study of immunogenicity and safety. Pediatr Infect Dis J 2014; 33:643–9; PMID:24717964; http://dx.doi.org/10.1097/INF.0000000000000276
  • Feroldi E, Pancharoen C, Kosalaraksa P, Watanaveeradej V, Phirangkul K, Capeding MR, Boaz M, Gailhardou S, Bouckenooghe A. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial. Hum Vaccin Immunother 2012; 8:929–37; PMID:22777096; http://dx.doi.org/10.4161/hv.20071
  • Guo SH, Yin JM, Chen HP, Zhen L, Qian CH, Wang WQ, Dong CM, Ze WY. The immune effect and systemic reaction of the freeze-derived inactivated Japanese encephalitis vaccine made from vero cells in an epidemic area. Chinese J Vaccin Immun 2002:3–6
  • Li WJ, Wang SQ, Wang ZY, Zhang EX, Xiao QY. Efficacy and safety evaluation of two kinds of Japanese encephalitis vaccine. Pract Prevent Med 2007:699–701
  • Qu SW. Immunogenicity compare between double and three-dose Inactivated Japanese encephalitis vaccine Chinese. J Vaccin Immun 2000; 27 (in Chinese)
  • Yang TL. Safety and immunogenicity of two types of Japanese encephalitis vaccine. Henan J Prevent Med 2005:328–9 (in Chinese)
  • Yin JM, Qian CH, Xu GY, Sun GY, Zhang J, Gu H, Diao LD, Chen HP, Ze WY. Adverse reaction and immunological efficacy of primary immunization with different doses of inactivated freeze-derived vero cell Japanese encephalitis vaccine. Chinese J Vaccin Immun 2002:7–9
  • Zhang HR, Wang LY, Chen LJ, Gao Jie, Xiao GQ, Huang Hui, Fan CY, Wang YM. Analysis on the immune effects and safety of the live attenuated and the inactivated Japanese encephalitis vaccines. Chinese J Vaccin Immun 2002:10–2
  • Zhang ZH, Kang JQ, Liu JR. Observation of JE live attenuated vaccine and inactivated vaccine effects and human vaccination reaction. Ning Med J 2012:632–3
  • ZHU FC. Inactivated Japanese encephalitis vaccine made from Vero cells: randomized, controlled phase II/III clinical trial 2008
  • Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088–101; PMID:7786990; http://dx.doi.org/10.2307/2533446
  • DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: An update. Contemp Clin Trials 2007; 105–114; PMID:16807131; http://dx.doi.org/10.1016/j.cct.2006.04.004
  • Lin HL. Jackknife Empirical Likelihood for the Variance in the Linear Regression Model. 2013.
  • Gatchalian S, Yao Y, Zhou B, Zhang L, Yoksan S, Kelly K, Neuzil KM, Yaïch M, Jacobson J. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine 2008; 2234–2241; PMID:18394765; http://dx.doi.org/10.1016/j.vaccine.2008.02.042
  • Kaltenböck A, Dubischar-Kastner K, Eder G, Jilg W, Klade C, Kollaritsch H, Paulke-Korinek M, Sonnenburg FV, Spruth M, Tauber E, Wiedermann U, Schuller E. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX→1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study. Vaccine 2009; 4483–4489; PMID:19486955; http://dx.doi.org/10.1016/j.vaccine.2009.05.034
  • Schuller E, Klade CS, Wölfl G, Kaltenböck A, Dewasthaly S, Tauber E. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: A randomized, observer-blind, controlled Phase 3 study. Vaccine 2009; 2188–2193; PMID:19200452; http://dx.doi.org/10.1016/j.vaccine.2008.12.062
  • Xu CL, Tang QY. Detection of residual cell matrix in Primary Hamster Kidney cell inactivated Japanese encephalitis vaccine. Chinese J Biol 2001:48–50
  • Newly accessible Japanese encephalitis vaccine will make saving children easier in developing countries. http://www.who.int/mediacentre/news/releases/2013/japanese_encephalitis_20131009/en/ 2013.
  • Zhao N, Yu SZ. Meta-analysis: A new quantitative approach to research synthesis. Chinese J Prevent Cont Chr Non-Commun Dis 1993:277–80
  • Solomon T. New vaccines for Japanese encephalitis. Lancet Neurol 2008; 7:116–8; PMID:18207104; http://dx.doi.org/10.1016/S1474-4422(08)70004-8
  • Palys KE, Berger VW. A note on the Jadad score as an efficient tool for measuring trial quality. J Gastrointest Surg 2013; 17:1170–1; PMID:23233271; http://dx.doi.org/10.1007/s11605-012-2106-0
  • Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352:609–13; PMID:9746022; http://dx.doi.org/10.1016/S0140-6736(98)01085-X
  • Wang D, Mou ZY, Zhai JX, Zong HX, Zhao XD. Study on STATA software in investigating publication bias in Meta-analysis. Modern Prevent Med 2008:2819–22
  • DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177–88; PMID:3802833; http://dx.doi.org/10.1016/0197-2456(86)90046-2
  • Demets DL. Methods for combining randomized clinical trials: Strengths and limitations. Stat Med 1987; 6:341–50; PMID:3616287; http://dx.doi.org/10.1002/sim.4780060325

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.